Adma Biologics (ADMA) Non-Current Debt (2011 - 2026)

Adma Biologics (ADMA) has 14 years of Non-Current Debt data on file, last reported at $69.3 million in Q4 2025.

• Quarterly Non-Current Debt fell 4.16% year-over-year to $69.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.3 million (down 4.16% YoY) and the FY2025 annual result came in at $69.3 million, down 4.16% from the prior year.
• Non-Current Debt declined to $69.3 million in Q4 2025, from $70.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $144.3 million in Q1 2023 to a low of $69.3 million in Q4 2025.
• A 5-year average of $110.9 million and a median of $116.0 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 50.56% — and 2024, when it slumped 44.61%.
• Tracing ADMA's Non-Current Debt over 5 years: stood at $94.9 million in 2021, then jumped by 50.56% to $142.8 million in 2022, then declined by 8.57% to $130.6 million in 2023, then tumbled by 44.61% to $72.3 million in 2024, then fell by 4.16% to $69.3 million in 2025.
• The last three Non-Current Debt figures came in at $69.3 million (Q4 2025), $70.1 million (Q3 2025), and $73.4 million (Q2 2025), per Business Quant data.